#Canada #Montreal #Congruence Therapeutics #Biotech Conferences #Protein Misfolding

Congruence Therapeutics to Showcase Innovations in Biotechnology

MONTREAL, April 22, 2025 – Congruence Therapeutics, a pioneering company harnessing computational techniques to develop innovative treatments for protein misfolding disorders, is gearing up for its participation in key upcoming investor conferences: the Citi Biotech Private Access Day and the Bloom Burton & Co. Healthcare Conference.

The Citi Biotech Private Access Day will take place on April 24, 2025, in a virtual format where members of Congruence's management team will engage with investors through one-on-one meetings. This event presents a prime opportunity for the company to discuss its strategies and advancements in the realm of biotechnology with interested stakeholders.

Following this, Congruence will also attend the Bloom Burton Healthcare Conference from May 4 to 6, 2025, where Dr. Clarissa Desjardins, the company's Chief Executive Officer, is scheduled to present on May 5 at 1:30 PM ET. The conference is expected to draw significant attention as it gathers industry professionals and investors, allowing Congruence to showcase its groundbreaking research and innovative solutions addressing significant health challenges.

Congruence Therapeutics is at the forefront of developing a unique pipeline of small molecule correctors aimed at treating conditions related to protein misfolding. These disorders include MC4R-deficient genetic obesity, GBA-driven Parkinson's disease, and α1-antitrypsin deficiency affecting lung and liver functions. Their proprietary platform, Revenir™, employs advanced algorithms to explore the three-dimensional conformation of proteins, identifying allosteric and cryptic sites that can be targeted to restore normal protein function.

The biotechnology firm’s commitment to addressing hard-to-drug targets is apparent in its ongoing multi-target research collaborations with leading pharmaceutical companies. These partnerships aim to discover small molecule correctors for metabolic diseases and solid tumors, diversifying the company’s therapeutic offerings and enhancing its market presence.

With a strong focus on innovative therapeutic solutions, Congruence Therapeutics is uniquely positioned to play a pivotal role in the evolution of biotechnology. By participating in prominent events like the Citi Biotech Private Access Day and the Bloom Burton Healthcare Conference, they aim to forge valuable connections and attract investments essential for advancing their research and bringing new therapies to the market. As they prepare for these critical discussions, the anticipation builds around Congruence's next steps in combating some of today's most challenging health issues.

For further information, visit www.congruencetx.com.

Media Contact:
Amy Conrad
Juniper Point
Email: [email protected]
Phone: 858-366-3243

Company Contact:
Charles Grubsztajn
Chief Operating Officer
Email: [email protected]